What is the half-life of Cortagen?

Cortagen has a half-life of Short (minutes as intact peptide; epigenetic effects persist), which is why it's typically administered once daily for optimal therapeutic effect.

How do I reconstitute Cortagen?

Add bacteriostatic water to the peptide vial slowly down the side. Typical reconstitution uses 2-3ml of water for a 5mg vial. Gently swirl, do not shake.

Healing & Recovery

Preclinical

Cortagen

Also known as: Cortagen tetrapeptide, AEDP

Overview

Key Facts

Primary Goal: A synthetic tetrapeptide bioregulator developed by Professor Vladimir Khavinson at the St

A synthetic tetrapeptide bioregulator developed by Professor Vladimir Khavinson at the St. Petersburg Institute of Bioregulation and Gerontology in Russia. Cortagen is designed to target the cerebral cortex, modulating gene expression related to neuronal function and potentially slowing age-related cognitive decline through epigenetic mechanisms. Half-Life Short (minutes as intact peptide; epigenetic effects persist) Typical Dose 10–50 mcg Frequency once daily Cycle Length 10-20 days, repeated 2-3 times per year

Dosing Information

Half-Life

Short (minutes as intact peptide; epigenetic effects persist)

Typical Dose

10–50 mcg

Frequency

once daily

Cycle Length

10-20 days, repeated 2-3 times per year

Administration Routes:

subcutaneousoral

Storage & Reconstitution

Unreconstituted (Powder)

Temperature2–8°C (36–46°F)

DurationUp to 3 months

Reconstituted (Mixed)

Temperature2–8°C (36–46°F)

Duration2-4 weeks

Research Summary

Preclinical

100 studies

Cortagen is part of Professor Khavinson's bioregulator peptide program, which has produced over 100 published studies on short peptides that modulate gene expression in tissue-specific ways. Research on Cortagen specifically has been published in Russian biomedical journals and the Bulletin of Experimental Biology and Medicine, demonstrating effects on cortical neuron gene expression patterns and neuroprotection in aging models. The bioregulator hypothesis — that short peptides can epigenetically restore youthful gene expression — remains an active area of research, primarily in Russia and Europe.